# US 2008/0305091 A1 · Poly-Epitope Peptide Derived from Thymidylate Synthase Having Immunological and Anti-Tumour Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305091 A1
- Document ID: US20080305091A1
- Status: Published application
- Kind: A1
- Application number: 11/814,919
- Filed: 2006-02-15
- Published: 2008-12-11
- Earliest claimed: 2005-02-16
- Assignees: Università Degli Studi Di Siena
- Inventors: Pierpaolo Correale; Maria Grazia Cusi; Guido Francini; Giorgio Giorgi
- Web page: https://patentgrep.com/patent/US20080305091A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns a peptide having anti-tumour activity and its related pharmaceutical compositions. In particular, the invention concerns a peptide with anti-tumour preventive and therapeutic activity, also in combination with other known anti-tumour compounds such as, for example, 5-fluorouracil.

## Claims

### Claim 1

A peptide included in the sequence YMIAHITGLFLDSLGFSTTLGDAHIYL (Seq. Id. No. 2) for medical use.

### Claim 2 (depends on 1)

The peptide according to claim 1 having the sequence from amino acid 19 to amino acid 27 of Seq. Id. No. 2, TLGDAHIYL.

### Claim 3 (depends on 1)

The peptide according to claim 1 having the sequence from amino acid 1 to amino acid 9 of Seq. Id. No. 2, YMIAHITGL.

### Claim 4 (depends on 1)

The peptide according to claim 1 having the sequence from amino acid 10 to amino acid 18 of Seq. Id. No. 2, FLDSLGFST.

### Claim 5 (depends on 1)

The peptide according to claim 1 having the sequence YMIAHITGLFLDSLGFSTTLGDAHIYL (Seq Id No. 2).

### Claim 6

A peptide having the sequence YMIAHITGLFLDSLGFSTTLGDAHIYL (Seq. Id. No. 2).

### Claim 7

A vector including, and capable of efficaciously expressing in an eukaryote cell, a nucleotide sequence coding for the peptide according to one of the preceding claims.

### Claim 8 (depends on 7)

The vector according to claim 7 whose nucleotide sequence is TACATGATTGCGCACATCACGGGCCTGTTTTTGGACAGCCTGGGATTCTCCACC ACTTTGGGAGATGCACATATTTACCTG (Seq ID No. 1).

### Claim 9 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition with preventive anti-tumour activity including a pharmaceutically effective amount of the peptide according to claims 1 to 5, and proper excipients and/or diluents and/or solubilising agents.

### Claim 10 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition with chemotherapeutic activity including a pharmaceutically effective amount of the peptide according to claims 1 to 5, and proper excipients and/or diluents and/or solubilising agents.

### Claim 11 (depends on 9, 10)

The pharmaceutical composition according to claim 9 or 10 including a further anti-tumour active drug.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11 wherein said further anti-tumour active ingredient is 5-fluorouracil.

### Claim 13

A method for obtaining in vitro cytotoxic T lymphocytes (CTLs) activated for TS, including the following steps:
a) take peripheral blood mononuclear cells (PBMCs) from a subject and culture them in vitro;
b) stimulate in vitro said PBMCs by exposing them to irradiated autologous dendritic cells previously exposed for opportune time to efficacious concentrations of the peptide according to claims from 1 to 5.

### Claim 14 (depends on 13)

Cytotoxic T lymphocytes activated for TS obtainable by means of the method according to claim 13.

### Claim 15 (depends on 14)

Use of the cytotoxic T lymphocytes activated for TS according to claim 14 for immunotherapy.
